Streetbeat News

Analyst Ratings

BTSG

Deutsche Bank analyst Pito Chickering initiates coverage on BrightSpring Health (NASDAQ:BTSG) with a Hold rating and a price target of $11.5.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 5:03 pm

URI

Analyst evaluations of United Rentals (NYSE:URI) show mixed sentiments with a recent shift towards more bullish perspectives. The average 12-month price target has been raised to $587.8, indicating a 22.14% increase from the previous target. Analysts from firms like Evercore ISI Group, Baird, and Barclays have adjusted their ratings and price targets, reflecting optimism about the company's market position, revenue growth, and financial performance. United Rentals, the world's largest equipment rental company, has shown strong revenue growth, net margin, and ROE, outperforming industry averages.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 5:01 pm

PTEN

Analyst ratings for Patterson-UTI Energy (NASDAQ:PTEN) show a mix of bullish to bearish sentiments. Recent adjustments have led to a decrease in the average 12-month price target to $15.25 from $17.33. The company's financial performance is strong, with significant revenue growth and effective debt management. Analysts from Evercore ISI Group, RBC Capital, Raymond James, and Goldman Sachs have adjusted their ratings and price targets, reflecting changing market conditions and company performance.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 5:01 pm

PCAR

Analysts have provided varied ratings for PACCAR (NASDAQ:PCAR) over the last quarter, with recent updates showing a shift towards more positive evaluations. The average 12-month price target for PCAR has increased to $107.67, reflecting a 15.03% rise from the previous target of $93.60. This change is based on updates from analysts at firms including Evercore ISI Group, UBS, Goldman Sachs, B of A Securities, JP Morgan, and Morgan Stanley, who have adjusted their price targets and ratings in response to PACCAR's market performance and financial indicators. PACCAR, known for its medium- and heavy-duty trucks, has shown a revenue growth rate of 4.37% and a net margin of 15.61%, outperforming industry averages.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 5:00 pm

TRUP

Four analysts have recently evaluated Trupanion (NASDAQ:TRUP), showing a mix of opinions with one somewhat bullish and three indifferent. The average 12-month price target for TRUP is now $31.0, reflecting a 2.48% increase from the previous target of $30.25. Analysts' actions include both raises and lowers in ratings and price targets, indicating a nuanced view of Trupanion's performance and potential. Trupanion, a provider of specialty insurance products for pets, has shown a revenue growth of 3.5% as of December 31, 2023, but lags behind industry peers and faces challenges in profitability and efficiency metrics.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 5:00 pm

ESS

Barclays has maintained its Underweight rating for Essex Property Trust (NYSE:ESS) but raised its price target from $224.00 to $225.00. Despite this, ESS shares are trading at $235.37, indicating a potential 4.41% decrease if it moves to the target price. Essex Property Trust owns and is developing a significant portfolio of apartment communities on the West Coast.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 5:00 pm

ZTS

Four analysts have recently updated their ratings on Zoetis (NYSE:ZTS), showing a mix of bullish and somewhat bullish sentiments. The average 12-month price target for Zoetis is now $234.00, marking a 6.36% increase from the previous target of $220.00. Analysts from Piper Sandler, Barclays, Goldman Sachs, and Jefferies have raised their price targets, reflecting optimism about Zoetis's future performance. The company, a leader in animal health products, has shown strong financial health with a positive revenue trend, high net margin, and exceptional ROE and ROA, despite a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 5:00 pm

GLSI

HC Wainwright & Co. has maintained its Buy rating for Greenwich LifeSciences (NASDAQ:GLSI) but lowered its price target from $38.00 to $36.00. Shares of GLSI have risen 4.98% in the last 24 hours to $11.80. The new price target suggests a potential increase of 205.08% from the current price. Greenwich LifeSciences is a clinical-stage biopharmaceutical company developing immunotherapies for breast cancer recurrences.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 5:00 pm

NOV

Piper Sandler has maintained its Neutral rating on NOV (NYSE:NOV) but lowered its price target from $25.00 to $22.00. NOV's shares have fallen 0.75% in the last 24 hours to $17.09. A price target of $22.00 represents a 28.73% increase from the current price. NOV is a global leader in supplying oil and gas drilling equipment, with over 60% of its revenue coming from international markets.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 5:00 pm

MPW

Medical Properties Trust (NYSE:MPW) has received mixed analyst ratings over the past three months, with a recent shift towards a more bearish outlook. The average 12-month price target is now $4.75, a significant decrease from the previous $8.33. Analysts from RBC Capital, Deutsche Bank, Mizuho, and JP Morgan have adjusted their ratings and price targets, reflecting concerns over the company's revenue decline, market capitalization, and financial performance despite its strong net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 5:00 pm